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Tuberculosis (TB) is a major global health threat. There is a need for the development of more efﬁcient
drugs for the sterilization of the disease’s causative agent, Mycobacterium tuberculosis (MTB). A more
comprehensive understanding of the bacilli’s nucleotide metabolic pathways could aid in the develop-
ment of new anti-mycobacterial drugs. Here we describe expression and puriﬁcation of recombinant
iunH-encoded nucleoside hydrolase from MTB (MtIAGU-NH). Glutaraldehyde cross-linking results indi-
cate that MtIAGU-NH predominates as a monomer, presenting varied oligomeric states depending upon
binding of ligands. Steady-state kinetics results show that MtIAGU-NH has broad substrate speciﬁcity,
accepting inosine, adenosine, guanosine, and uridine as substrates. Inosine and adenosine displayed posi-
tive homotropic cooperativity kinetics, whereas guanosine and uridine displayed hyperbolic saturation
curves. Measurements of kinetics of ribose binding to MtIAGU-NH by ﬂuorescence spectroscopy suggest
two pre-existing forms of enzyme prior to ligand association. The intracellular concentrations of inosine,
uridine, hypoxanthine, and uracil were determined and thermodynamic parameters estimated. Thermo-
dynamic activation parameters (Ea, DG
#, DS#, DH#) for MtIAGU-NH-catalyzed chemical reaction are pre-
sented. Results from mass spectrometry, isothermal titration calorimetry (ITC), pH-rate proﬁle
experiment, multiple sequence alignment, and molecular docking experiments are also presented. These
data should contribute to our understanding of the biological role played by MtIAGU-NH.
 2013 Elsevier Inc. All rights reserved.Introduction
Tuberculosis (TB1) is an infectious disease caused by the bacillus
Mycobacterium tuberculosis (MTB) and primarily affects the lungs
(pulmonary TB) but can infect other organ systems (extra-pulmon-
ary TB) [1]. The disease remains a major threat to global health,
and TB accounts for 2.0% of all Disability Adjusted Life Years (DALYs).It is the third leading cause of DALYs among infectious diseases after
human immunodeﬁciency virus (HIV) and malaria [2]. The World
Health Organization (WHO) estimated that in 2011, there were 8.7
million incident TB cases (13% of which occurred in those co-infected
with HIV), and 1.4 million deaths, 430,000 of which in HIV-positive
individuals [3]. The current regimen for treating TB was established
more than 30 years ago using drugs which were developed in theisability
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proved TB vaccine is the bacillus Calmette–Guerin (BCG), which
the WHO recommends in infants to prevent incident disease in chil-
dren. However, this vaccine confers variable protection to adoles-
cents and adults. Moreover, it is not effective in preventing
reactivation of the disease in those with latent TB infection [5,6].
There is an urgent need for the development of new and more
efﬁcient drugs for the treatment of TB. Strategies for the discov-
ery of new anti-mycobacterial targets include elucidation of the
role played by proteins in biochemical pathways essential for
mycobacterial growth and/or persistence [7]. Nucleotide meta-
bolic pathways provide a promising source for the discovery of
new antibacterial drug targets as the enzymes and pathways in-
volved frequently differ from their human counterparts. Purine
and pyrimidine salvage pathways in MTB remain an incompletely
explored possibility for drug development as purine and pyrimi-
dine biosynthesis are essential steps, supplying building blocks
for DNA and RNA synthesis [8]. Enzymes from these pathways
are thus attractive anti-tubercular drug targets [8]. Several homo-
logues to enzymes in the purine and pyrimidine pathways have
been identiﬁed in the genome sequence of MTB H37Rv [9]. A bet-
ter understanding of the characteristics of the enzymes involved
in purine and pyrimidine salvage pathways in MTB will aid in
the design of analogs that may selectively inhibit MTB replication
and survival. Ideally this class of compounds will be active
against strains of MTB that are resistant to drugs currently used
to treat the disease and, hopefully, also clear latent infections
[10].
Nucleoside hydrolases (or nucleoside N-ribohydrolases; NH)
catalyze the irreversible hydrolysis of N-glycosidic bond of ribonu-
cleosides forming a-D-ribose and the corresponding base [11]. NHs
are widely distributed in nature, and have been identiﬁed in a
number of sources, including bacteria [12–15], yeast [16–21], pro-
tozoa [16–20,22], insects [23], and mesozoans [24], indicating that
nucleoside hydrolysis plays an important role in many organisms.
Interestingly, neither nucleoside hydrolase activity nor the encod-
ing genes have ever been detected in mammals. Although found in
most organisms, the metabolic role of NHs has been well estab-
lished only in protozoan parasites such as Crithidia fascicula-
ta[16,18,25,26], Trypanosoma brucei brucei[19], and Leshmania
major[20]. Because parasitic protozoans lack the de novo pathway
to synthesize purine nucleosides, they rely on nucleoside hydrolase
to supply purine nucleosides by salvaging them from the host [16].
Thus, NH from parasitic protozoa in particular has been studied
extensively by X-ray crystallography, kinetic methods and site-di-
rected mutagenesis [11]. Nucleoside hydrolases have been classi-
ﬁed into three subclasses according to their substrate speciﬁcity:
the base-speciﬁc inosine–uridine preferring nucleoside hydrolase
(IU-NH) [16,20], the purine-speciﬁc inosine–adenosine–guanosine
preferring nucleoside hydrolase (IAG-NH) [27,28] and an inosine–
guanosine preferring nucleoside hydrolase (IG-NH) [17]. Recent
data suggest that this classiﬁcation has to be extended as there ex-
ists an increasing number of NHs that do not ﬁt in any of these
groups [14,24,29]. Moreover, there seems to be little correlation
between the level of amino acid identity and nucleobase speciﬁc-
ity. The iunH gene (MTB Rv3393) has been proposed by sequence
homology to encode a polypeptide chain with IU-NH activity [9],
and this gene product has been predicted not to be required for
in vitro growth of MTB [30]. In addition, high-resolution global
phenotypic proﬁling results have prompted the proposal that the
iunH-gene product is not required for in vitro growth in glycerol
and cholesterol (a critical carbon source during infection) media
[31]. However, as pointed out by Grifﬁn et al. [31], homologous
recombination and high-density mutagenesis genetic approaches
for deﬁning essential genes have advantages and limitations. Hu-
mans lack this enzyme and rely on a different set of enzymaticreactions to supply their nucleoside requirements. To the best of
our knowledge, there has been no formal proof as to ascertain
the correct assignment to the open reading frame of iunH gene in
MTB. In addition, the mode of action of this gene product has not
yet been reported. Accordingly, biochemical studies on iunH-gene
product seem to be worth pursuing.
Our manuscript describes polymerase chain reaction (PCR)
ampliﬁcation, cloning, expression and puriﬁcation of recombinant
iunH-encoded NH protein. Determination of metal identity and
concentration by inductively coupled plasma optical emission
spectroscopy suggest the presence of a Ca2+ ion per enzyme sub-
unit. Glutaraldehyde cross-linking results indicate that the recom-
binant protein is predominantly present in solution in a
monomeric state, having varied oligomeric states depending upon
binding of distinct ligands. Steady-state kinetics results, using a
continuous spectrophotometric assay, indicate that the recombi-
nant protein has broad substrate speciﬁcity, accepting inosine,
adenosine, guanosine, and uridine as substrates. Accordingly, the
recombinant protein will henceforth be referred to as MtIAGU-
NH. Inosine and adenosine displayed positive homotropic cooper-
ativity kinetics, whereas guanosine and uridine displayed hyper-
bolic saturation curves. Fluorescence spectroscopy measurements
of kinetics of ribose binding to MtIAGU-NH suggest two forms of
free enzyme in solution. Results for mass spectrometry, isothermal
titration calorimetry (ITC), pH-rate proﬁles, multiple sequence
alignment, and molecular docking experiments are also presented.
The intracellular concentrations of inosine, uridine, hypoxanthine,
and uracil in MTB bacilli were determined. Equilibrium constants,
standard free energy (DG), and intracellular concentration of a-ri-
bose to make the process favorable (DG < 0) were evaluated. Ther-
modynamic activation parameters (Ea, DG#, DS#, DH#) forMtIAGU-
NH-catalyzed chemical reaction are presented. It is hoped that the
data presented here may contribute to our understanding of MtIA-
GU-NH mode of action, thereby providing a solid basis for the ra-
tional design of inhibitors of this enzyme’s activity with potential
use as chemotherapeutic agents to treat TB. These inhibitors may
also be useful to chemical biologists interested in designing func-
tion-based chemical compounds to elucidate the biological role
of MtIAGU-NH in the context of whole MTB cells.Materials and methods
Gene ampliﬁcation, cloning, and protein expression
Synthetic oligonucleotide primers were designed to contain
NdeI (primer sense 50TCCATATGAGCGTCGTATTCGCCGACGTCG30)
and HindIII (primer antisense 50CCAAGCTTTCACGTTCGGCGCGCGAA
TCG30) restriction sites (highlighted in italics). The iunH gene
(Rv3393) was PCR ampliﬁed from total genomic DNA of MTB strain
H37Rv using Pfu DNA polymerase (Stratagene, Foster City, USA) in
the presence of 10% dimethyl sulfoxide (DMSO) (ﬁnal concentra-
tion). The PCR product (927 bp) was then puriﬁed from agarose
gel with a QIAGEN QIA quick gel extraction kit (Qiagen, Venlo,
Netherlands), cloned into the pCR-Blunt vector (Invitrogen, Life
Technologies, Grand Island, USA) and subcloned into the
pET-23a(+) expression vector (Novagen, Merck KGaA, Darmstadt,
Germany) using the NdeI and HindIII restriction enzymes (New
England Biolabs, Ipswich, USA). In order to conﬁrm the product’s
identity and integrity as well as to ensure that no mutations were
introduced in the cloned fragment the MTB iunH gene was se-
quenced with automatic DNA sequencing.
Escherichia coli C41(DE3) electro-competent cells were trans-
formed with recombinant pET23a(+) containing the iunH gene by
electroporation (Gene Pulser II; Capacitance Extender II; Pulse
Controller II, Bio-Rad Laboratories, Hercules, USA) and grown on
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medium (50 mL) was inoculated with a single colony and cells
were grown at 180 rpm at 37 C overnight. The culture (9 mL)
was inoculated in 500 mL of Terriﬁc Broth medium, with the same
antibiotic concentration, and grown in a shaker set at 180 rpm and
37 C until they achieved an OD600 reading of 0.4–0.6. The cells
were grown for an additional 18 h after induction with 0.5 mM iso-
propyl b-D-thiogalactopyranoside (IPTG) at 30 C. Cells were har-
vested by centrifugation at 8,000g for 30 min at 4 C and stored
at -20 C. Soluble and insoluble fractions were analyzed by 12%
Dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE)
[32].Protein puriﬁcation
HPLC was done using an ÄKTA System (GE Healthcare Life Sci-
ences, Pittsburgh, USA) and performed at 4 C. Approximately 5 g
of wet cell paste was suspended in 50 mL of 50 mM Tris HCl pH
7.5 (buffer A) containing a protease inhibitor cocktail tablet (Com-
plete EDTA-free, Roche Diagnostics, Basel, Switzerland) and gently
stirred for 30 min in the presence of 0.2 mg mL1 lysozyme (Sigma
Aldrich, Saint Louis, USA). Cells were disrupted by sonication (10
pulses of 10 s each at 60% amplitude) and centrifuged at 48,000g
for 30 min. To precipitate nucleic acids and ribonuclear proteins,
the supernatant was treated with 1% (w/v) streptomycin sulfate
(ﬁnal concentration) for 30 min under slow agitation and centri-
fuged at 48,000g for 30 min. The supernatant was dialyzed against
buffer A and loaded on a HiPrep Q-Sepharose Fast Flow anion ex-
change column (GE Healthcare Life Sciences, Pittsburgh, USA)
pre-equilibrated with buffer A, washed 3 column volumes (CV) of
the same buffer, and the adsorbed proteins were eluted with a lin-
ear gradient (0–100%) of 20 CV of 50 mM Tris HCl pH 7.5 contain-
ing 150 mM NaCl (buffer B) at 1 mL min1 ﬂow rate. The adsorbed
recombinant MtIAGU-NH was eluted at approximately 75 mM
NaCl and all fractions were analyzed by SDS–PAGE. The fractions
containing the MtIAGU-NH activity were pooled and concentrated
to a ﬁnal volume of 7 mL using a 50 mL stirred ultraﬁltration cell
(Millipore, Billerica, USA) with a 10 kDa cutoff ﬁlter, and loaded
on a HiLoad Superdex 200 26/60 size exclusion column (GE Health-
care Life Sciences, Pittsburgh, USA), previously equilibrated with
buffer A. Proteins were isocratically eluted with 1 CV of buffer A
at 0.3 mL min1 ﬂow rate, and the fractions containing the target
protein were pooled and loaded on a High Resolution Mono Q
16/10 anion exchange column (GE Healthcare Life Sciences, Pitts-
burgh, USA), previously equilibrated with buffer A. The column
was washed with 1 CV, adsorbed proteins were eluted with a linear
gradient (0–100%) of 20 CV of buffer B, and the target protein was
eluted with 70 mM NaCl. The active fractions containing homoge-
neousMtIAGU-NH were concentrated and dialyzed against 0.5 L of
50 mM Tris HCl pH 7.5 containing 50 mM NaCl (buffer C). Protein
concentration was determined by the method of Bradford using
the Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, USA) and bovine
serum albumin as standard [33].MtIAGU-NH identiﬁcation by mass spectrometry
The homogeneous MtIAGU-NH was submitted to electrospray
ionization mass spectrometry (ESI-MS) to conﬁrm the enzyme’s
identity. The protein was digested with trypsin and the resulting
peptides were separated and analyzed by liquid chromatography
associated with mass spectrometry with induced fragmentation
collision. The results were used to identify the amino acid se-
quence through search software (Protein Discover, Thermo Fisher
Scientiﬁc, Waltham, USA).Inductively coupled plasma optical emission spectroscopy (ICP-OES)
analysis of metal content
ICP-OES (PerkinElmer Optima 4300 DV, PerkinElmer Sciex, Can-
ada) measurements were employed to assess metal identity and
concentration. Prior to these measurements, recombinant homoge-
neous MtIAGU-NH was extensively dialyzed against 50 mM Tris
HCl pH 7.5 and concentrated by ultraﬁltration to a protein concen-
tration of 2 mg mL1.
MtIAGU-NH quaternary structure
Determination of MtIAGU-NH molecular mass in solution was
performed injecting 100 lL protein suspension (11 lM homoge-
neous recombinantMtIAGU-NH in 50 mM Tris HCl pH 7.5 contain-
ing 50 mM NaCl) into a HighLoad 10/30 Superdex-200 gel
chromatography (GE Healthcare Life Sciences, Pittsburgh, USA)
at 0.4 mL min1 ﬂow rate and isocratic elution with 1 CV of
50 mM Tris HCl pH 7.5 containing 200 mM NaCl. Protein elution
was monitored at 215, 254, and 280 nm. The LMW and HMW Gel
Filtration Calibration Kits (GE Healthcare Life Sciences, Pittsburgh,
USA) were used to prepare a calibration curve, measuring the elu-
tion volumes (Ve) of standard proteins (ferritin, catalase, aldolase,
ovalbumin, coalbumin, and ribonuclease A). These values were
used to calculate their respective partition coefﬁcients (Kav, Eq.
(1)). Blue dextran 2000 (GE Healthcare Life Sciences, Pittsburgh,
USA) was used to determine the void volume (V0). Vt is the total
bead volume of the column. The Kav value for each protein was
plotted against their corresponding molecular mass to obtain an
estimate for free MtIAGU-NH molecular mass in solution.
Kav ¼ Ve  V0V t  V0 ð1Þ
Glutaraldehyde cross-linking studies were performed to obtain
estimates for the oligomeric state of both free MtIAGU-NH and en-
zyme in the presence of products. The method described by Fadou-
loglou et al. was employed using crystallization plates [34]. In
short, the reservoir was ﬁlled with 120 lL of 25% (v/v) glutaralde-
hyde acidiﬁed with HCl, and a drop of 10 lL of protein suspension
(15 lM homogeneous recombinant MtIAGU-NH in 50 mM Tris HCl
pH 7.5 containing 50 mMNaCl) was placed on the cover slip, which
in turn was used to seal the well (forming a hanging drop inside
the well). Drops of 10 lL of protein suspension in the presence of
4 mM of ribose, hypoxanthine, uracil, adenine, and guanine were
employed to determine the oligomeric states of MtIAGU-NH in
the presence of products. The plates were incubated at 30 C for
different time intervals and protein drops were subsequently ana-
lyzed by 12% SDS–PAGE.
Steady-state kinetic parameters
All chemicals in enzyme activity measurements were pur-
chased from Sigma Aldrich (Saint Louis, USA). MtIAGU-NH activity
was measured by a continuous spectrophotometric assay in quartz
cuvettes using a UV–visible Shimadzu spectrophotometer UV2550
equipped with a temperature-controlled cuvette holder.
The kinetic properties of MtIAGU-NH for inosine, adenosine,
guanosine, and uridine were spectrophotometrically determined
using the difference in absorption between the nucleoside and
the purine or pyrimidine base. MtIAGU-NH enzyme activity was
measured in the presence of varying concentrations of substrate
in 50 mM Tris HCl pH 7.5 containing 50 mM NaCl at 30 C. The
reaction was started with addition of concentrations of MtIAGU-
NH that yielded decreasing linear absorbance time courses for
the conversion of nucleoside substrates into products in a total vol-
ume of 0.3 mL. The De values (mM1cm1) used were: inosine,
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guanosine, 0.11 at 300 nm [16]. All assays were performed in
duplicate. One unit of enzyme activity (U) was deﬁned as the
amount of enzyme catalyzing the conversion of 1 lmol of sub-
strate into product per minute at 30 C.
The experimental data were either ﬁtted to the Hill equation
(Eq. (2)) for a sigmoidal saturation curve or to the Michaelis–Men-
ten equation (Eq. (3)) for a hyperbolic saturation curve [35,36]. For
these equations, v is the steady-state velocity, Vmax is the maximal
velocity, S is the substrate concentration, KM is the Michaelis–Men-
ten constant, n is the Hill coefﬁcient (indicating the cooperative in-
dex), and K0.5 is the substrate concentration in which
v = 0.5Vmax[35,36]. All data were analyzed by nonlinear regression
using the SigmaPlot software (SigmaPlot 9.01, Systac Software, Inc.,
Melbourne, USA).
v ¼ Vmax½S
n
Kn0:5 þ ½Sn
ð2Þ
v ¼ Vmax½S
KM þ ½S ð3Þ
As no saturation for uridine could be detected by the continu-
ous spectrophotometric assay, ITC measurements were carried
out. MtIAGU-NH activity measurements were thus performed
using an ITC200 microcalorimeter (Microcal, Inc., Pittsburgh, USA)
at 30 C and a syringe of 39.7 lL total volume with the mixture
stirring at 500 rpm. A heating reference of 11 lcal s1 was used
in all experiments. After an initial delay of 60 s, reactions were ini-
tiated by injecting 7.2 lL of enzyme solution (86.2 lM) into the
sample cell (for a total volume of 203 lL) loaded with substrate
(2.5 mM uridine). A second enzyme injection was performed after
a 3 h lag time to obtain the correct baseline and also to determine
the dilution heat of enzyme in solution, which was subtracted from
the total reaction heat. The apparent enthalpy of reaction (DHapp)
is determined from area under the curve divided by the total num-
ber of moles of uridine (same as dividing the total heat generated
in the reaction by the amount of product formed when the sub-
strate is totally consumed) [37].
To measure enzyme activity, after an initial delay of 60 s, reac-
tions were initiated by injecting 3 lL of enzyme solution
(34.5 lM) into the sample cell (for a total volume of 203 lL) loaded
with variable substrate concentrations (5–150 mM uridine). Sub-
strate and enzyme solutions were suspended in the same buffer
(50 mMTris HCl pH 7.5 containing 50 mMNaCl) tominimize the ef-
fects of heat dilution. The reference cell (200 lL) was loaded with
MilliQ water for all experiments. The initial velocity for MtIAGU-
NH was measured by taking the difference in heat ﬂux measured
between the base line and 60 s, and the maximal heat ﬂux after en-
zyme solution injection into the calorimeter cell containing the
substrate medium at variable concentrations. A steady state is
reached when the enzyme velocity remains constant (Origin 7,
OriginLab Corp., USA). Experiments were carried out in duplicate.
The heat transferred during the enzyme-catalyzed reaction was di-
rectly proportional to the reaction rate and can be described by Eq.
(4), where DHapp is the reaction enthalpy variation, V is the calori-
metric cell volume and [P] is the product concentration, and dQ/
dt represents the heat ﬂow that is proportional to the rate of prod-
uct formation (d[P]/dt) [37].
d½P
dt
¼ 1
VDHapp
dQ
dt
ð4Þ
The kinetic parameters (Vmax and KM) were obtained by ﬁtting
the calorimetric data to the Michaelis–Menten equation (Eq. (3))
using nonlinear least square regression analysis in the Sigmaplot
9.01 software program. The deﬁnition for unit of enzyme activity
was the same as for the spectrophotometric assays.Fluorescence spectroscopy
Data from cross-linking experiments demonstrates that the en-
zyme can form dimers, trimers or tetramers in solution in the pres-
ence of products. We thus deemed appropriate to try to study
whether or not this equilibrium could be detected by a different
experimental approach. As the binding of ribose (a common prod-
uct of nucleoside hydrolysis) to free MtIAGU-NH causes a quench
in tryptophan ﬂuorescence, ﬂuorescence spectroscopy was em-
ployed to study the kinetics of MtIAGU-NH:ribose binary complex
formation. Fluorescence titration at varying ribose concentrations
(1–56 mM) in a 2 mL solution containing 1 lM MtIAGU-NH in
50 mM Tris–HCl pH 7.5 and 50 mM NaCl was carried out at
30 C. Excitation and emission wavelengths were, respectively,
280 and 333 nm. Slits for excitation and emission were, respec-
tively, 3 and 5 nm. Control measurements were performed under
the same conditions, except that no ligand was added. These values
were subtracted from those obtained in the presence of enzyme.
MtIAGU-NH:ribose binary complex formation was characterized
by a monophasic quench in protein ﬂuorescence. Accordingly, the
data were ﬁtted to a single exponential function, yielding the ob-
served rate constants (kobs). The kobs values were ﬁtted as a func-
tion of varied substrate concentration (A) to an equation
describing a hyperbolic decay (Eq. (5)), in which Kd is the intrinsic
dissociation constant, and k2 and k-2 are, respectively, limiting for-
ward and reverse ﬁrst-order rate constants for an isomerization
process between two forms of free enzyme that must occur before
substrate binding [38–41].
kobs ¼ k2KdAþ Kd
 
þ k2 ð5Þ
The overall dissociation constant (KD(overall)) is given by the ratio
of the product of the concentrations of all free species to the sum-
mation of the concentrations of all complexes [41], as shown in Eq.
(6) for the mechanism depicted in Fig. 5A.
KDðoverallÞ ¼ ð½E
 þ ½EÞ½ribose
½E  ribose þ ½E ribose ð6Þ
Since the interaction of ribose with the E⁄ isomer ofMtIAGU-NH
is assumed to be negligible so that [Eribose] [E⁄ribose], Eq.
(6) reduces to Eq. (7).
KDðoverallÞ ¼ ð½E
 þ ½EÞ½ribose
½E ribose ð7Þ
The equilibrium constant (K2) for the conversion from E⁄ to E,
and Kd are deﬁned in Eq. (8) and Eq. (9), respectively
K2 ¼ ½E½E ¼
k2
k2
ð8Þ
Kd ¼ ½E½ribose½E ribose ¼
k1
k1
ð9Þ
Rearranging Eqs. (8) and (9) to give, respectively, [E⁄] = [E]/K2
and [Eribose] = ([E][ribose])/Kd, and substituting them into Eq.
(7), yields an expression for KD(overall) (Eq. (10)) [41].
KDðoverallÞ ¼ Kd 1K2 þ 1
 
ð10ÞIntracellular concentrations in MTB
In order to quantify the intracellular concentration of inosine,
uridine, hypoxanthine and uracil in the bacilli, the MTB H37Rv lab-
oratory strain was cultured as described by Rodrigues-Junior et al.
[42]. Brieﬂy, MTB colonies cultured in Ogawa solid medium were
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80 (Sigma–Aldrich, Saint Louis, USA). We assessed the number of
viable organisms in an aliquot of this cell suspension by plating se-
rial dilutions on Middlebrook 7H10 agar (Difco, Sparks, USA) plates
containing 10% Middlebrook oleic acid–albumin–dextrose–cata-
lase (OADC) enrichment (Becton–Dickinson, Frankin Lakes, USA).
Plates were incubated at 37 C for three weeks prior to counting
the number of MTB colony-forming units (CFU). The MTB suspen-
sion was autoclaved at 121 C for 20 min, followed by sonication (3
pulses of 10 s, at an amplitude value of 21%), prior to chromato-
graphic analysis. An HPLC equipped with a quaternary pump,
DAD detector, degasser, column oven and an automatic injection
system (all HPLC components and software Chromeleon from
Thermo Scientiﬁc (Sunnyvale, USA) was used in this set of exper-
iments). Stock standard solutions (400 lM) of inosine, uridine,
hypoxanthine, and uracil were prepared by diluting each standard
in ultrapure water. Standard solutions were prepared by diluting
the stock solution in ultrapure water to give ﬁnal concentrations
of 0.048, 0.097, 0.195, 0.390, 0.781, 1.562, 3.125, 6.25, and
12.50 lM in a ﬁnal volume of 1.0 mL.
Chromatographic separations were carried out using an RP col-
umn (250 mm, 4.6 mm, 5 lm Sephasil peptide ST C-18, GE Health-
care Life Sciences, Pittsburgh, USA) at 20 C. The mobile phase
was 0.1% glacial acetic acid (Merck, Darmstadt, Germany) in bot-
tle A and a mixture of methanol:water 80:20 (v/v) in bottle B. A
ﬂow rate of 0.5 mL min1 was employed and a linear gradient up
to 100% B was started at 33 min and maintained until 50 min.
The column was equilibrated with 100% A for 10 min. The DAD
detector was set at 254 nm and a full scan was continuously per-
formed with a total run time of 60 min.
Determination of equilibrium constants for MtIAGU-NH
In order to determine reaction spontaneity of MtIAGU-NH, the
equilibrium constants (Keq) were identiﬁed at the point of equilib-
rium between inosine, ribose and hypoxanthine or between uri-
dine, ribose and uracil. The Keq was measured at 30 C in 50 mM
Tris–HCl pH 7.5 containing 50 mM NaCl by ﬁxing the ratio of
[hypoxanthine]/[inosine] or [uracil]/[uridine] at 1 and varying the
ratio of [ribose]/[water]. The enzyme velocity was determined at
various [ribose]/[water] ratios with ribose concentration ranging
from 1 mM to 660 mM. All measurements were performed in
duplicate. The point at which the curve crosses the abscissa is
equal to Keq (no net enzyme reaction). The values of Keq permit
to obtain estimates for the standard free energy (DG) using Eq.
(11), in which R is the gas constant (8.324 J K1 mol1; or
1.987 cal K1 mol1) and T is the temperature in Kelvin
(T = C + 273.15).
DG
 ¼ RT lnKeq ð11Þ
As intracellular concentrations of uridine, uracil, inosine and
hypoxanthine were determined, the free energy of the reaction
(DG) could be estimated from Eq. (12), in which DG is the stan-
dard free energy. Assuming dilute solutions, we could tentatively
regard the intracellular water concentration as at a constant value
of 55.5 M ((1000 g L1)/(18.015 g mol1)).
DG ¼ DG þ RT ln ½base½a-ribose½nucleoside½H2O
 
ð12ÞActivation energy
The activation energy (Ea) was assessed by measuring the vari-
ation of kcat of MtIAGU-NH as a function of temperature. Initial
velocity measurements were thus carried out in the presence ofinosine (6.0 mM), uridine (2.7 mM), adenosine (2.0 mM), and gua-
nosine (3.0 mM), at temperatures ranging from 15 to 40 C (from
288.15 to 313.15 K). All assays were performed in duplicate. The
Ea was calculated from the slope (Ea/R) of the Arrhenius plot
(Fig. 7) ﬁtting the data to Eq. (13), in which R is the gas constant
(8.314 J mol1 K1) and the constant A represents the product of
the collision frequency (Z) and a steric factor (p) based on the col-
lision theory of enzyme kinetics [43]. It should be pointed out that
here it is assumed a simplistic approach to explain a complex phe-
nomenon and that A is independent of temperature.
ln kcat ¼ lnA EaR
 
1
T
ð13Þ
The enthalpy (DH#), entropy (DS#), and Gibbs free energy (DG#)
of activation were estimated using the following equations derived
from the transition state theory of enzymatic reactions [43]:
DH# ¼ Ea  RT ð14ÞDG# ¼ RT ln kB
h
þ ln T  ln kcat
 
ð15Þ
and
DS# ¼ DH
#  DG#
T
ð16Þ
Energy values are in kJ mol1, with kcat in s1, to conform to the
units of the Boltzmann (1.3805  1023 J K1) and Planck
(6.6256  1034 J s1) constants and R is as for Eq. (13). Errors on
DG# were calculated using Eq. (17) [43].
ðDGÞErr ¼
RTðkcatÞErr
kcat
ð17ÞpH-rate proﬁle
Prior to determining the dependence of the kinetic parameters
on pH values, the pH-rate proﬁles, MtIAGU-NH enzyme stability
was assessed over a wide pH range (4.5–10.0) by pre-incubating
the enzyme for 2 min at 30 C in 100 mM 2-(N-Morpholino)eth-
anesulfonic Acid (MES)/N-2-Hydroxyethylpiperazine-N’-2-ethane-
sulfonic Acid (HEPES)/2-(N-Cyclohexylamino)ethanesulfonic Acid
(CHES) buffer mixture [44], and monitoring the activity in 50 mM
Tris–HCl pH 7.5 containing 50 mM NaCl. These pre-incubation
experiments were carried out to identify denaturing values and en-
sure enzyme stability over the pH range studied. The pH-rate pro-
ﬁles were determined by measuring initial velocities in the
presence of varying inosine concentrations (1–200 lM) in
100 mM MES/HEPES/CHES buffer mixture over the following pH
values: 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 [44]. All measurements
were performed in duplicate or triplicate. The pH-rate proﬁle was
generated by plotting log(kcat) versus the pH values (from 5.5 to
9.5), and data were ﬁtted to Eq. (18), in which y is the apparent ki-
netic parameter, C is the pH-independent plateau value of y, H is
the hydrogen ion concentration, and Ka is the apparent acid disso-
ciation constant for the ionizing group.
log y ¼ log C
1þ HKa
 !
ð18Þ
It appears pertinent to point out that the determination of stea-
dy-state kinetic parameters, ITC measurements, ﬂuorescence spec-
troscopy, determination of equilibrium constants, and activation
energy data acquisition were all carried out at a constant pH value
(7.5), in which the kinetic parameters are pH-independent.
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The amino acid sequences of protozoan parasite nucleoside
hydrolases (C. fasciculata (U_43371) and L. major (AY_603045.1)),
whose three-dimensional structures have previously been solved
or for which mutagenesis studies have been reported to verify
essential residues, were included in the alignment to compare with
MtIAGU-NH. Multiple amino acid sequence alignment was per-
formed with Clustal W software [45], using the Blossum matrix
for amino acid substitutions and the default parameters to identify
essential residues for nucleoside substrates binding, as well to infer
possible structural similarities.Fig. 1. SDS–PAGE (12%) analysis for the three chromatographic steps of puriﬁcation
of recombinant MtIAGU-NH (33 kDa) that yielded homogeneous protein, Lane 1,
Molecular Weight Protein Marker (Fermentas); lane 2, crude extract; lane 3, Q-
Sepharose anion exchange column; lane 4, Superdex-200 size exclusion; lane 5,
MonoQ High Resolution anion exchange column.
Table 1
Puriﬁcation protocol of recombinant MtIAGU-NH. Typical results of a three-step
puriﬁcation protocol for 5 g wet cell paste from 0.5 L media.
Step Total
protein
(mg)
Total
activityª
(U)
Speciﬁc
activity
(U mg1)
Puriﬁcation
(fold)
Yield
(%)
Crude extract 243.4 5.1 0.02 1 100
Q-Sepharose FF 36.2 0.9 0.03 1.19 17.6
Superdex 200 3.8 0.3 0.07 3.38 5.9
Mono-Q 3.3 0.4 0.12 5.52 7.8
All experiments were performed in duplicate.Molecular modeling studies
The homology modeling approach, implemented in the MODEL-
LER 9v10 program, was used to build a structural model for MtIA-
GU-NH [46]. The protocol included the generation of 10 models. All
models were submitted to the energy function DOPE evaluation
that is implemented in the MODELLER 9v10 aiming to choose the
best structures. Furthermore, we used the MOLPROBITY webserver
PROCHECK [47], ANOLEA [48], VERIFY-3D [49], PROSAII [50] pro-
grams to assess stereo chemical quality of the models. Molecular
docking experiments were performed to analyze the binding mode
of nucleoside substrates to MtIAGU-NH protein. Ligands, Ca2+, and
MtIAGU-NH were prepared using AutoDockTools1.5.2 while dock-
ing simulations were performed with AutoDock4.2, allowing ligand
ﬂexibility. The validation procedure was made with the crystal
structure of C. fasciculata IU-NH associated with a transition-state
inhibitor (PDB ID: 2MAS). For all simulations the 3-D grid dimen-
sion used to deﬁne MtIAGU-NH active site and for scoring function
evaluation was 60  60  60 with spacing of 0.375. The Lamarck-
ian Genetic Algorithm was employed as the docking algorithm
with 20 runs and the remaining parameters set to their default val-
ues, except for ga_num_evals, which was set to 2,500,00. Intermo-
lecular hydrogen bonds were assessed using the program LIGPLOT
[51]. All ﬁgures were generated using the PyMol program [52].ª One enzyme unit is deﬁned as the amount of MtIAGU-NH that converts 1 lmol of
uridine to uracil at 30 C per minute.Results and discussion
Ampliﬁcation, cloning, expression, and puriﬁcation of MTB nucleoside
hydrolase (MtIAGU-NH)
The iunH gene was ampliﬁed from the MTB genome in the pres-
ence of 10% DMSO in the reaction mixture. The DMSO co-solvent
helps overcome polymerase extension difﬁculties that result from
secondary DNA structures while also enhancing the denaturation
of Guanosine–Cytosine-rich DNAs [53], which is consistent with
the 65.6% G + C content of the MTB genome [31]. A PCR ampliﬁca-
tion fragment consistent with the expected size for the MTB iunH
sequence (927 bp) was detected on agarose gel (data not shown)
and the fragment was cloned into pCR-Blunt vector, and subcloned
into pET23a(+) expression vector between the NdeI and BamHI
restriction sites. Accurate construction without mutations was
conﬁrmed with enzyme restriction analysis and automatic DNA se-
quence analysis.
SDS–PAGE analysis showed expression of a protein in the solu-
ble fraction with an apparent subunit molecular mass of 33 kDa
in agreement with the predicted molecular mass of MtIAGU-NH
(32,937.5 Da). The heterologous expression in E. coli C41(DE3) host
cells was achieved after 18 h of cell growth upon reaching an OD600
of 0.4–0.6 at 30 C in Terriﬁc Broth medium with IPTG induction
(data not shown). The pET expression system makes use of apowerful T7 polymerase, under control of the IPTG-inducible la-
cUV5 promoter for transcription of genes of interest, which are
positioned downstream of the bacteriophage T7 late promoter
[54]. Recombinant MtIAGU-NH was puriﬁed to homogeneity
(Fig. 1) using a three-step puriﬁcation protocol that employed
standard anionic exchange and size exclusion columns, with a pro-
tein yield of 7.8% (Table 1). Homogeneous enzyme was stored at
80 C with no loss of activity.MtIAGU-NH identiﬁcation by mass spectrometry
The homogeneous recombinant protein, digested with trypsin,
was submitted to ESI-MS (analysis as described in the experimen-
tal procedures section) and showed identity and integrity of MtIA-
GU-NH. 213 spectra were obtained and identiﬁed with 19 different
peptides from the MtIAGU-NH amino acid sequence. These pep-
tides covered approximately 52% of the whole sequence and the
subunit molecular mass of MtIAGU-NH was determined as
32,839.0 Da (data not shown). The results of mass spectrometry
analysis combined with the amino acid sequencing demonstrated
removal of the N-terminal methionine residue, and that the puri-
ﬁed protein was indeed MtIAGU-NH.
Fig. 2. MtIAGU-NH quaternary structure determination by glutaraldehyde cross-linking experiments. Incubation times (numbers in black) are shown at the bottom of each
lane. Lane numbers are shown in white against a solid black background. M: Page Ruler Marker (Fermentas). (A) ApoMtIAGU-NH; (B)MtIAGU-NH incubated with ribose; (C)
MtIAGU-NH incubated with hypoxanthine; (D) MtIAGU-NH incubated with adenine; (E) MtIAGU-NH incubated with uracil; (F) MtIAGU-NH incubated with guanine.
Formation of dimers, trimers and tetramers can be visualized in (B–F) in addition to monomers that appear in (A).
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Determination of metal concentration and identity by ICP-OES
yielded 2.3 ± 0.1 mg L1 of Ca2+. These results indicate the presence
of one mol of Ca2+ (57.4 lM) per mol of enzyme subunit (60.7 lM),
thereby suggesting that MtIAGU-NH is a metalloenzyme.MtIAGU-NH quaternary structure
A value of 23.8 kDa for the apparent molecular mass of homoge-
neous recombinant MtIAGU-NH was estimated by gel ﬁltration
chromatography, ﬁtting the elution volume of the single peak to
Eq. (1) (data not shown). This result suggests that MtIAGU-NH is
a monomer in solution, since ESI-MS analysis suggested a value
of 32,839.0 Da for the subunit molecular mass of the recombinant
protein. The monomeric state of MtIAGU-NH is in contrast to
nucleoside hydrolases from other organisms such as C. fasciculata
and L. major, which have been demonstrated to be homotetramers
in solution [20,27], or Trypanosoma vivax which has been demon-
strated to be a homodimer in solution [28].
Cross-linking experiments were pursued to conﬁrm the gel ﬁl-
tration chromatography results. The glutaraldehyde cross-linking
results show that MtIAGU-NH is a monomer in solution, even after
60 min of incubation time in the absence of the reaction products(Fig. 2A). Dimers, trimers and tetramers were visualized on SDS–
PAGE gel stained with Coomassie brilliant blue when MtIAGU-NH
was incubated for 20 min in the presence of the reaction products
ribose (Fig. 2B), hypoxanthine (Fig. 2C), adenine (Fig. 2D), uracil
(Fig. 2E), and guanine (Fig. 2F). Goodey and Benkovic reported that
the binding of an allosteric effector results in the redistribution of
protein conformational ensembles and alters the rates of their
interconversion, thereby modulating the geometry of active and
binding sites [55]. As suggested by the cross-linking results, the
protein oligomeric state appears to be modulated by ribose, hypo-
xanthine, adenine, uracil, and guanine products, resultant from the
hydrolysis of their corresponding nucleosides catalyzed by MtIA-
GU-NH (see next section).Steady-state kinetic parameters
Saturation curves for MtIAGU-NH speciﬁc activity plotted
against increasing concentrations of inosine (Fig. 3A), adenosine
(Fig. 3B), guanosine (Fig. 3C), and uridine (Fig. 3D) were shown
to obey distinct functions. Steady-state kinetic parameters are gi-
ven in Table 2. Fitting the sigmoidal data for inosine and adenosine
saturation curves to Eq. (2) yielded values of 2.2 mM for K0.5 and
0.49 s1 for kcat for inosine, and 0.70 mM for K0.5 and 0.26 s1 for
kcat for adenosine. These results suggest positive homotropic
Fig. 3. Steady-state kinetic constants forMtIAGU-NH. (A) Varied inosine concentrations; (B) varied adenosine concentrations; (C) varied guanosine concentrations; (D) varied
uridine concentration.MtIAGU-NH velocity measurements employed absorbance spectroscopy for inosine, adenosine and guanosine; and ITC for uridine. The inset of D gives
the heat ﬂow as a function of time (lcal s1) for the hydrolysis of uridine into uracil and ribose. The arrow indicates the time at which the second injection took place (see
experimental procedures).
P.L. Wink et al. / Archives of Biochemistry and Biophysics 538 (2013) 80–94 87cooperative kinetics for inosine and adenosine. To the best of our
knowledge sigmoidal proﬁles for purine and pyrimidine substrate
saturation curves have never been observed for NH enzymes pro-
duced by parasitic protozoa. It is tempting to suggest that the lim-
iting value for the Hill coefﬁcient (n) is 4 as MtIAGU-NH can form
tetramers in solution in the presence of hypoxanthine (Fig. 2C) and
adenine (Fig. 2D) products. The n values of 2.9 and 3.4 indicate
strong positive homotropic cooperativity for, respectively, inosine
and adenosine. Saturation curves for increasing guanosine
(Fig. 3C) and uridine (Fig. 3D) concentrations followed hyperbolic
Michaelis–Menten kinetics. Values for the steady-state constants
were calculated ﬁtting the data to Eq. (3), yielding KM and kcat val-
ues of, respectively, 1.6 mM and 0.96 s1 for guanosine, and 25 mM
and 9.9 s1 for uridine (Table 2).
As the curve for uridine did not achieve saturation with a con-
tinuous spectrophotometric assay, we employed a thermodynamic
approach using ITC to be able to compare the kinetic parameters of
uridine with the other substrates. Downward baseline displace-
ment after enzymatic injection indicates an exothermic reaction;
theMtIAGU-NHDHapp was9.5 (±0.4)  104 cal mol1 for uridine
hydrolysis (Fig. 3D – inset). The kinetic parameters obtained by ITC
for the puriﬁedMtIAGU-NH enzyme are shown and compared with
the other substrates (inosine, adenosine, and guanosine) in Table 2.
ITC is a sensitive technique that directly determines the thermody-
namic and kinetic parameters of enzymatic reactions by measuring
the heat absorbed or released during a chemical reaction (binding,
dilution, or transformation) [37]. As described by Bianconi, calori-
metric enthalpy is the sum of the different heat effects that takeplace during a reaction [56]. Other researchers have reported that
calorimetric and spectrophotometric data agree well [56,57].
Accordingly, ITC was employed to compare the kinetic parameters
of MtIAGU-NH using uridine as a substrate.
The activity measurements demonstrate that the MTB iunH
gene product has broad substrate speciﬁcity (Table 2), and was
thus (as pointed out in the Introduction section) designated as
MtIAGU-NH enzyme. Interestingly, even though the KM value for
uridine is larger than for the other nucleosides tested, its maxi-
mum velocity value is also larger. For instance, the speciﬁcity con-
stant (kcat/KM) value for uridine is approximately 396 M1 s1
whereas it is 600 M1 s1 for guanosine, suggesting that the appar-
ent second-order rate constants for these substrates are somewhat
similar. Although the speciﬁcity constants for inosine and adeno-
sine could not be estimated because saturation curves were sig-
moidal; the kcat values for inosine, adenosine and guanosine are
similar, and the K0.5 values for inosine and adenosine are in the
same concentration range of the KM value for guanosine.
Many enzymes that are subject to regulatory control have pro-
ven to be oligomeric proteins [58]. Interestingly, gel ﬁltration chro-
matography suggested that apo MtIAGU-NH is monomeric in
solution, whereas cross-linking results showed that this enzyme
might shift to different oligomeric states in the presence of prod-
ucts. Unfortunately, cross-linking studies could not be performed
in the presence of nucleosides as there would be catalysis in an
aqueous solution. It has been shown that polymerization of an en-
zyme in the presence of a modiﬁer can provide a mechanism for
allosteric behavior [59,60]. Brown and Reichard showed that the
Table 2
Kinetic constants for the substrates of MtIAGU-NH.
Substrate K0.5 (mM) na KM
(mM)
Vmax
(U mg1)
kcat (s1)
Inosineb 2.2 ± 0.1 2.9 ± 0.5 – 0.89 ± 0.05 0.49 ± 0.02
Adenosineb 0.70 ± 0.03 3.4 ± 0.6 – 0.47 ± 0.02 0.26 ± 0.01
Guanosineb – – 1.6 ± 0.3 1.7 ± 0.1 0.96 ± 0.05
Uridinec – – 25 ± 3 18.1 ± 0.4 9.9 ± 0.4
All measurements were performed in duplicate.
ª n = the Hill coefﬁcient.
b These results were collected by spectrophotometry.
c This result was collected by ITC.
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aggregation in the presence of the negative modiﬁer dATP [61].
Most enzymes showing allosteric behavior (altered activity in the
presence of ligands that bind at a site other than the catalytic cen-
ter) are oligomeric, or have such high molecular weights that it is
probable that they are oligomeric. Because of this association of
oligomeric structure with allosteric behavior, allosteric mecha-
nisms are usually discussed in terms of interaction between pro-
tomers [58].Fluorescence spectroscopy
The kinetics of binding of ribose to MtIAGU-NH was evaluated
by ﬂuorescence spectroscopy. The change in protein ﬂuorescence
upon ribose binding to MtIAGU-NH was characterized by a mono-
phasic quench in tryptophan ﬂuorescence (Fig. 4 – Inset(A)), and
the data were thus ﬁtted to a single exponential function. The
dependence of the apparent rate constants (kobs) on ribose concen-
tration showed a hyperbolic decrease (Fig. 4). The dependence of
the kobs on product concentration can be utilized to infer whether
or not two forms of free enzyme are present in solution. If free en-
zyme exists in equilibrium between two forms, E and E⁄, the for-
mer interacting signiﬁcantly with substrate and the latter
interacting negligibly (Fig. 5A), one expects a decrease in the kobs
value as ligand concentration is raised [38–41]. On the other hand,
if there is one form of free enzyme in solution (Fig. 5B), increasingFig. 4. Kinetics ofMtIAGU-NH-ribose binary complex formation, showing the dependence
representative curve for the monophasic quench in protein ﬂuorescence upon ribose (7.4
amplitude of ﬂuorescence signals as a function of ribose concentrations.substrate levels are accompanied by a hyperbolic increase in the
value of kobs [38–41]. The binding kinetics data for MtIAGU-NH:ri-
bose binary complex formation is consistent with the mechanism
depicted in Fig. 5A, which is described by the concerted mecha-
nism of symmetry model proposed by Monod et al., that predicts
two free MtIAGU-NH isomers in equilibrium, E and E⁄, with prod-
uct (ribose) binding effectively to E and negligibly to E⁄ [62]. In this
mechanism, isomerization is thought to be slower than the binding
steps. This model predicts that the rate constant of association of
ribose to MtIAGU-NH is limited by the ﬁrst-order isomerization
rate constant (k2) from E⁄ to E as ribose concentration approaches
inﬁnity, because only E binds substrate considerably. Data ﬁtting to
Eq. (5) yielded values for k2, k-2 (the rate constant for the isomeri-
zation from E to E⁄ in Fig. 5A), and Kd (Table 3).
Analysis of the proposed model for ribose binding to MtIAGU-
NH (Fig. 5) allows evaluation of the overall dissociation constant
(KD(overall)) for the MtIAGU-NH:ribose binary complex formation,
which provides information on possible additional steps in the
binding sequence. A value of KD(overall) = 2.2 mM was obtained
using Eq. (10). Fluorescence spectroscopy measurements could
not be carried out for the products hypoxanthine or uracil due to
the fact that, different from ribose, they absorb in the wavelengths
used to assessMtIAGU-NH ﬂuorescence, resulting in inner-ﬁlter ef-
fects that precluded reliable data collection. It is tempting to sug-
gest that the E¡E equilibrium prior to ribose binding may be
reporting on the different oligomeric states of MtIAGU-NH demon-
strated by the glutaraldehyde cross-linking results (Fig. 2B). How-
ever, whether or not the pre-existing equilibrium process of
different oligomeric forms of MtIAGU-NH in solution can be as-
cribed to an equilibrium between less active or more active of en-
zymes needs more experimental evidence. The amplitude of the
spectroscopic signals of the monophasic quench in protein ﬂuores-
cence plotted against ribose concentrations showed a hyperbolic
increase (Fig. 4 – Inset(B)). Fitting the amplitude data to a hyper-
bolic equation yielded a value for the dissociation constant of
10 ± 2 mM. As this value is somewhat larger than KD(overall)
(2.2 mM), additional step(s) that was(were) not taken into account
in the simple model given in Fig. 5A may have to be considered.
However, it appears not to be warranted to put forward any more
complex model based on the experimental results presented.of the observed association rate constant on ribose concentration. Inset (A) shows a
mM) binding to MtIAGU-NH (1 lM). Inset (B) shows the hyperbolic increase of the
Fig. 5. Two possible allosteric mechanisms. (A) The symmetry or concerted mode
with two forms of free enzyme at equilibrium in solution. (B) The sequential
induced-ﬁt model, with only one form of free enzyme and a slow isomerization
the enzyme-ligand binary complex.
Table 3
Rate and equilibrium parameters of MtIAGU-NH:ribose
binary complex formation.
Parametera Value ± standard error
Kd 1.7 ± 0.4 mMb
k2 5.2 (±0.5)  103 sb
k2 1.40 (± 0.08)  103 sb
KD(overall) 2.2 ± 0.1 mMc
K2 3.7 ± 0.4d
a All parameters are derived from the kinetics of ribose
binding to MtIAGU-NH.
b Fitting observed association rate constants to Eq. (5).
c Calculated by Eq. (10).
d Obtained from Eq. (8).
Table 4
Intracellular concentrations of substrates and products of the MtIAGU-NH-catalyzed
reaction in MTB bacilli.
Minimum
concentration (mM)
Maximum
concentration (mM)
Substrates Inosine 17.8 ± 0.3 285 ± 5
Uridine 196 ± 39 3134 ± 618
Products Hypoxanthine 27.5 ± 0.5 440 ± 8
Uracil 19.6 ± 0.1 313 ± 2
All measurements were performed in triplicate.
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or
ofAccordingly, further approaches will have to be pursued to ascer-
tain whether or not there is(are) additional step(s) to be included
in the minimal model given in Fig. 5A.Intracellular concentrations in MTB
The intracellular concentrations of inosine, uridine, hypoxan-
thine, and uracil in MTB bacilli were determined by HPLC prior
to determining equilibrium constants for MtIAGU-NH. According
to the standard curves, retention times for inosine, uridine, hypo-
xanthine, and uracil were 42.90, 33.40, 24.52, and 13.18 min,
respectively (data not shown). The intracellular concentrations of
inosine, hypoxanthine, uridine and uracil are given in Table 4. It
should be pointed out that we have assumed that each cell volume
could be represented by a cylinder (V = pr2h, in which ‘‘r’’ repre-
sents the radius and ‘‘h’’ the length). These values were considered
to be in the range 0.3–0.6 lm for diameter and 1–4 lm for length
[1]. The lowest values were employed to estimate the maximum
concentrations and the largest ones to estimate the minimum con-
centrations (Table 4).Determination of MtIAGU-NH equilibrium constants
The ratio of [hypoxanthine]/[inosine] or [uracil]/[uridine] was
ﬁxed at 1, and the ratio of [ribose]/[water] was varied from
1.8  105 to 1.2  102 for the reaction with the purine or
1.8  105 to 6  103 for the reaction with the pyrimidine to
determineMtIAGU-NH equilibrium constants. Hydrolytic reactions
are regarded as experimentally irreversible because of the rather
large concentration of water in comparison to other reactants. Plot-
ting the MtIAGU-NH enzyme activity as a function of [ribose]/
[water] ratio gives a straight line (Fig. 6), in which the point at
which this line crosses the abscissa (no enzyme activity) gives an
estimate for the equilibrium constant. This analysis yielded values
of 0.0076 for Keq of inosine (Fig. 6A) and 0.0037 for Keq of uridine
(Fig. 6B). The standard free energy (DG) can thus be calculated
by Eq. (11).This analysis gives values at 30 C (303.15 K) for DG
of 12.3 kJ mol1 (2.94 kcal mol1) for inosine and 14.1 kJ mol1
(3.37 kcal mol1) for uridine, which suggests that both reactions
are not spontaneous. If we take into account the intracellular con-
centrations of inosine and uridine substrates and the reaction
products (hypoxanthine and uracil) found in the HPLC quantiﬁca-
tion in MTB bacilli, we can employ Eq. (12) to obtain estimates
for free energy of the reaction (DG). The intracellular concentration
of uridine is approximately 10-fold larger than the concentration of
uracil (Table 4). The concentration of inosine is slightly lower than
the concentration of hypoxanthine (Table 4). We have been unable
to both determine the MTB intracellular concentration of a-ribose
and ﬁnd a value for its concentration in the literature we searched.
Notwithstanding, a minimum intracellular concentration for a-ri-
bose needed to make the process favorable (DG < 0) can be esti-
mated. The intracellular concentration of a-ribose should be
smaller than approximately 270 mM for inosine hydrolysis and
than 2 M for uridine hydrolysis. Accordingly, it appears to be rea-
sonable to conclude that these processes are likely favorable in
the intracellular milieu of MTB bacilli. There are, however, other
MTB enzymes that catalyze reactions that could provide free bases
and nucleosides. For instance, purine nucleoside phosphorylase
(PNP) is involved in the metabolism of both purine and pyrimidine
[63]. PNP catalyzes the reversible phosphorolysis of the N-glyco-
sidic bond of a-purine (deoxy)ribonucleosides to generate ß-
(deoxy)ribose 1-phosphate and the corresponding purine bases
[64,65]. The PNP from MTB has been shown to be more speciﬁc
to natural 6-oxopurine nucleosides and synthetic compounds,
and does not catalyze the phosphorolysis of adenosine [66].
Activation energy
We assessed the activation energy for the enzyme-catalyzed
chemical reaction by measuring the dependence of kcat on temper-
ature for four substrates (Fig. 7). The activation energies of MtIA-
GU-NH reactions were calculated by determining the slope (Ea/
R) of the Arrhenius plots. The thermodynamic activation parame-
ters evaluated using Eqs. (13)–(17) are given in Table 5.
The Ea values for inosine, adenosine, guanosine and uridine (Ta-
ble 5) represent the minimum amount of energy necessary to ini-
tiate the MtIAGU-NH-catalyzed chemical reaction. It should,
however, be pointed out that larger concentrations of uridine could
not be employed in the enzyme assay due to its large KM value
(25 mM) and limited solubility in aqueous solutions. The Ea values
for adenosine and guanosine are somewhat larger than for inosine
and uridine (Table 5), suggesting lower activation energy for the
former substrates. The values of free activation energy (DG#) rep-
resent the energy barrier required for reactions to occur. The DG#
values can also be regarded as the variation of the Gibbs energy be-
tween the activated enzyme:substrate(s) activated complex and
enzyme:substrate(s) in the ground state. No differences in DG#
Fig. 6. Plot of speciﬁc activity against [ribose]/[water], for acquisition of the equilibrium constant of the MtIAGU-NH reaction. (A) Enzyme activity measurements for
[hypoxanthine]/[inosine] = 1 at varying [ribose]/[water] ratios; (B) enzyme activity measurements for [uracil]/[uridine] = 1 at varying [ribose]/[water] ratios.
Table 5
Thermodynamic activation parameters for the MtIAGU-NH-catalyzed chemical reac-
tion at 30 C (303.15 K).
Parameter Inosine Adenosine Guanosine Uridine
Ea (kJ mol1) 32 ± 2 70 ± 4 46.8 ± 0.7 31 ± 2
DH# (kJ mol1) 29 ± 1 67.1 ± 3.7 44.3 ± 0.7 28.5 ± 1.7
DG# (kJ mol1) 59.9 ± 0.1 59.9 ± 0.1 59.9 ± 0.1 59.9 ± 0.2
DS# (J mol1) 102 ± 5 24 ± 45 52 ± 2 104 ± 10
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similar overall free activation energy for hydrolysis of inosine,
adenosine, guanosine and uridine substrates.
The facility of the activated enzyme:substrate(s) complex for-
mation depends on whether the degree of order is lower
(DS# > 0) or higher (DS# < 0) than the enzyme:substrate(s) in the
ground state [67]. The activation entropy DS# values were foundFig. 7. Arrhenius plots for the four substrates (temperature dependence oto be negative for inosine, guanosine, and uridine; whereas it
was positive for adenosine (Table 5). The larger positive value for
DH# (unfavorable process) was found for adenosine, which appears
to be compensated for by the positiveDS# value (Table 5). Interest-
ingly, as the values ofDG# for the four nucleosides tested are equal,
there appears to be enthalpy–entropy compensation, resulting in
temperature-independent DG# values, which has commonly been
found in protein:ligand interactions [68].pH-rate proﬁle
The pH dependence of kinetic parameters for inosine was car-
ried out to probe acid/base chemistry in MtIAGU-NH mode of ac-
tion. MtIAGU-NH was stable over the pH range used in the pH-
rate proﬁles (data not shown). Although we have tried to measure
enzyme activity in a broader pH range (4.5–10), reliable data could
only be obtained for pH values ranging from 5.5 to 9.5. Allf log kcat): inosine (N), adenosine (d), uridine (s), and guanosine (4).
Fig. 8. The pH dependence data of log kcat for inosine hydrolysis were ﬁtted to Eq. (17), yielding a pKa value of 5.7.
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dependence of kcat is concerned with the chemical step and its va-
lue follows the pKa of groups that play critical roles in catalysis. The
pH-rate data of kcat for inosine hydrolysis showed a proﬁle of a
curve with slope of 1 that goes to a slope of zero as a function of
increasing pH values (Fig. 8). Fitting the pH-rate data to Eq. (18)
yielded a value of 5.7 (±0.4) for pKa. However, as no reliable data
could be collected below pH 5.5, only a rough estimate of the
apparent pKa value on the acidic limb could be obtained. Notwith-
standing, the pH-rate data suggest that protonation of a group with
pKa value of approximately 5.7 prevents catalysis. In addition, since
inosine has no ionizable groups over this pH range, this pKa value
represents an ionizable group on the enzyme that is involved in
catalysis.
It has been suggested that a histidine residue (His241) is essen-
tial for activity of inosine–uridine-preferring nucleoside hydrolaseFig. 9. Sequence alignment of nucleoside hydrolases from M. tuberculosis (Mtb), C. fasc
involved in the ribose binding mode are indicated by black solid circles (d). Amino acids
role in nucleoside hydrolase catalysis is indicated by a black solid cross (+). Overall iden
(64.18% similarity), and from M. tuberculosis and L. major is 28.04% (61.99% similarity).(IU-NH) from C. fasciculata[18]. The His241Ala mutation caused a
2100-fold loss in kcat for inosine and this residue was proposed
to act as a proton donor for leaving group activation in C. fasciculata
IU-NH catalysis [18]. The values for K0.5 (substrate concentration in
which v = 0.5Vmax) and n (Hill coefﬁcient) showed no obvious
trends in pH-dependence plots of MtIAGU-NH enzyme activity
(data not shown). These results are in agreement with the role of
His241 of C. fasciculata IU-NH as being only in catalysis and not
substrate binding [18]. In addition, sequence alignment shows that
the His241 of C. fasciculata IU-NH is conserved in both L. major IU-
NH and MtIAGU-NH (Fig. 9). On the other hand, it has been pro-
posed for the inosine–adenosine–guanosine-preferring nucleoside
hydrolase (IAG-NH) from T. vivax that Asp10 is the general base
in the reaction mechanism that abstracts a proton from a nucleo-
philic water molecule [27]. Moreover, the data for C. fasciculata
IU-NH showed a bell-shaped pH proﬁle (range: 5.6–10.5) foriculata (Cfa), and L. major (Lma). The family signature is highlighted. Amino acids
involved in substrate recognition are shaded. The conserved His residue that plays a
tity between nucleoside hydrolases from M. tuberculosis and C. fasciculata is 28.35%,
Table 6
Intermolecular contacts for MtIAGU-NH:nucleoside binary complexes.
Dockings Hydrogen
bonds
Electrostatic
interactions
Hydrophobic interactions
Adenosine Glu160 Asp13 Asp14, Asn38, His77, Phe80, His81,
Met149, Gln156, Trp161, Asn162,
Tyr225, His241, Asp242
Guanosine Asp13,
Asn38
His77
Glu160 Asp14, Phe80, His81, Thr123,
Met149, Gln156, Trp161, Asn162,
Tyr225, Asp242
Inosine Asn38,
Gln156,
Asn162
Glu160,
Trp161
His77, Phe80, His81, Met149,
Leu189
Uridine Glu160,
Tyr225
Asp13, Asn38, His77, Phe80, His81,
Met149, Gln156, Asn162, His229,
His241
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during which the enzyme requires one group to be deprotonated
(pK 7.1) and one group to be protonated (pK 9.1) [25]. Accordingly,
site-directed mutagenesis should be carried out to ascertain
whether the His241 plays any role in MtIAGU-NH catalysis, and
the possibility that groups with larger pKa values may play any role
in either catalysis or substrate binding.
Homology modeling
A structural model for the 308-amino-acid polypeptide chain of
MtIAGU-NH was built to try to provide support for the probable
involvement of amino acid residues in the enzyme’s mode of ac-
tion. Alignment was performed to evaluate protein similarities,
identify enzyme signature and search for appropriate templates
using the PROSITE web server [69]. Sequence alignment data
(Fig. 9) suggested that C. fasciculata IU-NH (PDB ID: 2MAS) [70] is
an appropriate template for molecular modeling studies.
The topology of MtIAGU-NH is similar to C. fasciculata IU-NH
[26]. MtIAGU-NH has 12 a-helices (a1 (Ile12-Ala23), a2
(Val41-Cys55), a3 (Lys79-His81), a4 (Ala103-Ser113), a5
(Thr127-Arg134), a6 (Ala138-Leu142), a7 (Trp161-Arg164), a8
(Glu168-Thr175), a9 (Leu189-Arg193), a10 (Pro199-Ser207), a11Fig. 10. Molecular model for MtIAGU-NH associated with nucleosides. (A) MtIAGU
NH:guanosine. The a-helices are colored in light green and b-sheets in light blue. These
atom (carbon = yellow, nitrogen = blue, oxygen = red and hydrogen = white) and repre
interactions are illustrated as sticks and colored by atom (carbon = grey, nitrogen = blue,
generated with PyMol [52].(Arg216-Ala231), a12 (Asp242-Met250), and a13 (Pro290-
Phe304), in addition to nine b-strands (b1 (Asp26-Thr35), b2
(Pro61-Gly65), b3 (Gly120-Val122), b4 (Leu146-Gly150), b5
(Gln182-Val186), b6 (Leu254-Arg258), b7 (Thr261-Asp265), b8
(Ala269-Asp273) and b9 (Arg283-Asp289). MtIAGU-NH subunit is
folded into a single-domain globular structure that can be divided
into three regions (see Graphical Abstract) as has been suggested
for C. fasciculata IU-NH [26]. The ﬁrst consists of an a,b core com-
prising segments b1–b6, a1–a6, b7 and a10. The second is a lobe
consisting of the four a-helices (a7–a9 and a11) that appears to
have a purely structural function, shielding the hydrophobic resi-
dues of the core domain from the solvent. The third region consists
of two short segments of b structure, strands b8 and b9, and forms
the subunit–subunit interface [26].Molecular docking experiments
To compare differences in the binding of substrates to MtIAGU-
NH, the patterns of hydrogen bonds, and electrostatic and hydro-
phobic interactions were studied. Table 6 gives a summary of inter-
actions for binary complexes formed between MtIAGU-NH and
adenosine, guanosine, inosine and uridine.
Most of the hydrogen bonds and electrostatic interactions for
MtIAGU-NH:nucleoside binary complexes involve the ribose moi-
ety of substrates, which is more buried into the enzyme’s active
site than the base moiety (Fig. 10). A similar binding pattern was
observed when comparing the amino acid residues involved in
the ribose binding mode in MtIAGU-NH (Asp13, Asn38, Glu160,
Asn162) with nucleoside hydrolases of different organisms. This
suggests that molecular dockings experiments reproduced the cor-
rect binding mode of the ribose moiety of nucleosides. The analysis
of base portion for each substrate molecule revealed some differ-
ences. Contrary to the ribose portion, adenine makes no hydrogen
bonds contacts withMtIAGU-NH amino acids (>3.5 Å). On the other
hand, hydrophobic contacts could be observed for adenine (Phe80,
Trp161, Tyr225). Guanine makes one hydrogen bond (Asp13).
Hypoxanthine makes two hydrogen bonds with Gln156 and
Asn162. Uracil makes two hydrogen bonds with Glu160 and
Tyr225 (Fig. 10).-NH:adenosine; (B) MtIAGU-NH:uridine (C) MtIAGU-NH:inosine; (D) MtIAGU-
secondary structures are represented as ribbon diagrams. All ligands are colored by
sented as sticks. The residues that are making hydrogen bonds or electrostatic
oxygen = red and hydrogen = white). Calcium ion is shown as a green sphere. Image
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The complete genome sequencing of MTB H37Rv strain has
accelerated the study and validation of molecular targets aimed
at the rational design of anti-TB drugs [9]. Target-based rational
design of new agents with anti-TB activity includes a thorough
analysis of functional and structural components of MTB enzymes.
Enzyme inhibitors make up roughly 25% of the drugs marketed in
United States [71]. Enzymes catalyze multistep chemical reactions
to achieve rate accelerations by stabilization of transition state
structure(s) [72]. Accordingly, mechanistic analysis should always
be a top priority for enzyme-targeted drug programs aiming at the
rational design of potent enzyme inhibitors. Moreover, the recogni-
tion of the limitations of high-throughput screening approaches in
the discovery of candidate drugs has rekindled interest in rational
design methods [73]. However, the ﬁrst step to validate enzyme
targets must include experimental data demonstrating that the
gene predicted by in silico analysis to encode a particular protein
catalyzes the proposed chemical reaction.
Although our understanding of purine metabolism in MTB is
still incomplete, it is known that this bacterium expresses all en-
zymes for the de novo synthesis of purine nucleotides [10]. Accord-
ingly, MTB is not a purine auxotroph [74]. However, little is known
about the nutritional adaptability of MTB in the course of TB infec-
tion [75]. Whether MTB relies on complex nutrient molecules up-
take from host (salvage pathways) or on synthesis of essential
molecules from simple and passive diffusible precursors (de novo
synthesis pathways) is still not clear. The de novo synthesis is a
high-energy demanding process. Whether MTB will sway between
de novo or salvage pathways is an unanswered question. However,
it is tempting to suggest that the ability of MTB of scavenging free
extracellular nitrogenous bases via the salvage pathway is likely to
play a role in survival under conditions of low energy availability,
rapid multiplication, or nutrient starvation to maintain the nucle-
otide pool [76]. Attempts to ascertain the role of MtIAGU-NH in
MTB survival in vivo during both active and latent TB should how-
ever be pursued to provide a solid experimental basis for its role.
Interestingly, the broad substrate speciﬁcity of MtIAGU-NH may
point to a pivotal metabolic role in MTB. It has been pointed out
that inhibitors of the enzymes that disrupt the purine salvage path-
way would be expected to be toxic to latent MTB [10]. At any rate,
a combination of inhibitors of enzymes of both de novo synthesis
and salvage pathways are more likely to be effective against active
and latent TB infection.
Understanding the mode of action ofMtIAGU-NH will inform us
on how to better design inhibitors targeting this enzyme. In addi-
tion, understanding the mode of action of an enzyme can be used
to inform functional annotation of newly determined sequences
and structures, to select appropriate enzyme scaffolds for engi-
neering new functions, and to reﬁne deﬁnitions in the current EC
classiﬁcations [77]. Bacterial nucleoside hydrolases have been pro-
posed to be attractive drug targets because they are not present in
humans, which rely on a different set of enzymatic reactions to
supply their nucleoside requirements. Accordingly, the results here
presented may contribute to both function-based drug design and
functional genomic efforts. The results here presented may also
help chemical biologists to design function-based chemical com-
pounds to carry out either loss-of-function (inhibitors) or gain-
of-function (activators) experiments to reveal the biological role
of MtIAGU-NH in the context of whole MTB cells [78].Acknowledgments
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